Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Selcia Adds Director of Discovery Role | Contract Pharma
Breaking News, Promotions & Moves

Selcia Adds Director of Discovery Role

Davis brings extensive R&D expertise

John Davis has been appointed to the newly created role of director of discovery at Selcia Ltd. Mr. Davis joins the company from Convergence Pharmaceuticals, where he served as head of biology and was a co-founder of the company.
 
Mr. Davis’ research has focused on cardiovascular, oncology and CNS disorders. He gained 20 years of drug discovery experience at SmithKline Beecham and GlaxoSmithKline across range of target classes including ion channels, GPCRs, kinases and proteases. He was responsible for the discovery of 11 small molecule and biologic development candidates and the preclinical pharmacology supporting two assets.
 
At GSK he was director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and also managed several large collaborations with universities.
 
Dr. Hans Fliri, chairman and chief executive officer of Selcia, said, “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal. ”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters